FDA Pharmacoepidemiology Deputy Director To Be ODE V's Bull
This article was originally published in The Pink Sheet Daily
Executive Summary
When the Office of Drug Evaluation V is eliminated as part of the anticipated reorganization of the Office of New Drugs, Jonca Bull is expected to move to the open post, which will report to Paul Seligman.